Cuprina Holdings announces product classification from SFDA for MEDIFLY

Cuprina Holdings (CUPR) announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Cuprina’s 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority for MEDIFLY, the Company’s medical-grade maggot debridement therapy. The SFDA has classified MEDIFLY as a Medical Device-Drug combination product, with the primary mode of action regulated under the medical device framework. This classification, which allows the Company to finalize the scientific and technical requirements necessary for the commercial distribution of MEDIFLY across Saudi Arabia’s healthcare network, is a critical milestone in Cuprina’s expansion strategy for the Middle East and North Africa region. The Company is also pleased to announce the appointment of Enming Yong to its Medical and Scientific Advisory Board. Dr. Yong is a highly respected Consultant in the Department of Endocrinology at Tan Tock Seng Hospital and serves as an Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine, both located in Singapore.